Articles

In August Daiichi Sankyo and Eli Lilly and Company launched U.S. sales of Effient (prasugrel), a new antiplatelet medication to prevent stent thrombosis, which clinical studies show to be more...

Ruptured vulnerable plaque (VP) is blamed for the majority of acute myocardial infarctions and many strokes, but there is extensive debate over which modalities are best suited to detect these...

Stenting of lesions at coronary vessel bifurcations is one of the most challenging percutaneous interventions, along with a high risk of procedural complications and restenosis. Several companies...

Over the past year several new drug-eluting stents (DES) stents have been released and SYNTAX trial data proved DES compare as well as coronary artery bypass graft surgery (CABG) in patient...

Metal stents are foreign objects that can irritate vessels and cause stent thrombosis, prevent vessel remodeling, prevent future surgical interventions, can fatique and suffer strut fractures, and...

The polymer coating on drug-eluting stents (DES) used to carry the antiproliferative drugs cause an increased risk of stent thrombosis, months or even years after a stent is implanted. This has...

September 15, 2009 – Fluid monitoring with OptiVol Fluid Status Monitoring is a more accurate predictor of worsening heart failure compared to daily weight monitoring in heart failure patients...

September 9, 2009 - Integrated backscatter (IBS) images were acquired with transesophageal echocardiography (TEE) and 3-dimensional image reconstruction to identify an increase in atrial...

September 11, 2009 – Abbott said yesterday it reached an $410 million agreement to purchase Evalve Inc., the global leader in the development of devices for minimally invasive repair of cardiac...

Gregg W. Stone, M.D., offered a preview Sept. 10 of some of the key, late-breaking clinical trials and trends in interventional cardiology that will be presented during the Transcatheter...